ESC 365 - What is the evidence for empagliflozin in HFpEF?

Open Access

What is the evidence for empagliflozin in HFpEF?

Session: SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Speaker: Professor G. Rosano (London, GB)

Sponsored by Boehringer Ingelheim & Eli Lilly

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Giuseppe Rosano

St Georges Medical School, London (United Kingdom of Great Britain & Northern Ireland)

106 presentations

25 followers

3 more presentations in this session

Introduction and recap.

Speaker: Professor S. Anker (Berlin, DE)

Implementing empagliflozin for HFpEF treatment in my practice.

Speaker: Professor M. Boehm (Homburg, DE)

Panel discussion.

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

SGLT2 inhibitors in practice (part 2): how do we implement new treatments in HFpEF?

Speakers: Professor G. Rosano, Professor S. Anker, Professor M. Boehm, Professor S. Anker

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources